Vistagen Therapeutics, Inc. SEC filings VTGN
Vistagen Therapeutics, Inc. has 908 filings in SEC EDGAR's recent list, going back to Sep 11, 2007. Its latest annual report, Form 10-K, was filed on Jun 15, 2026 for the period ended Mar 31, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (exit or restructuring costs, other events). The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Jul 31, 2026 | — |
| DEF 14A | Proxy statement | Jul 31, 2026 | Jul 31, 2026 |
| DEFA14A | Additional proxy material | Jul 28, 2025 | — |
| DEF 14A | Proxy statement | Jul 28, 2025 | Sep 9, 2025 |
| DEFA14A | Additional proxy material | Jul 17, 2024 | — |
| DEF 14A | Proxy statement | Jul 17, 2024 | Aug 26, 2024 |
| DEF 14A | Proxy statement | Apr 16, 2024 | May 29, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 5, 2024 | May 29, 2024 |
| DEFA14A | Additional proxy material | Jul 28, 2023 | — |
| DEF 14A | Proxy statement | Jul 28, 2023 | Sep 25, 2023 |
| DEFA14A | Additional proxy material | Oct 6, 2022 | — |
| DEFA14A | Additional proxy material | Aug 31, 2022 | — |
| DEF 14A | Proxy statement | Aug 31, 2022 | Oct 14, 2022 |
| PRE 14A | Preliminary proxy statement | Aug 22, 2022 | Oct 14, 2022 |
| DEFA14A | Additional proxy material | Jul 29, 2021 | — |
| DEF 14A | Proxy statement | Jul 29, 2021 | Sep 17, 2021 |
| DEF 14A | Proxy statement | Jan 14, 2021 | Jan 14, 2021 |
| PRE 14A | Preliminary proxy statement | Dec 31, 2020 | Dec 31, 2020 |
| DEFA14A | Additional proxy material | Jul 27, 2020 | — |
| DEF 14A | Proxy statement | Jul 27, 2020 | Sep 17, 2020 |
| DEFA14A | Additional proxy material | Jul 25, 2019 | — |
| DEFA14A | Additional proxy material | Jul 25, 2019 | — |
| DEF 14A | Proxy statement | Jul 23, 2019 | Jul 26, 2019 |
| PRE 14A | Preliminary proxy statement | Jul 12, 2019 | Sep 5, 2019 |
| DEFA14A | Additional proxy material | Jul 27, 2018 | — |
| DEF 14A | Proxy statement | Jul 27, 2018 | Jul 27, 2018 |
| DEFA14A | Additional proxy material | Aug 4, 2017 | — |
| DEF 14A | Proxy statement | Aug 4, 2017 | Aug 4, 2017 |
| PRE 14A | Preliminary proxy statement | Jul 17, 2017 | Jul 17, 2017 |
| DEF 14A | Proxy statement | Aug 8, 2016 | Sep 26, 2016 |
| DEF 14A | Proxy statement | Aug 11, 2015 | Aug 11, 2015 |
| PRE 14A | Preliminary proxy statement | Jul 28, 2015 | Jul 24, 2015 |
| DEF 14A | Proxy statement | Oct 12, 2011 | Oct 11, 2011 |
| PRE 14A | Preliminary proxy statement | Sep 2, 2011 | Sep 2, 2011 |
Showing 34 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VTGN (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- NV
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1411685
- Former names
- Excaliber Enterprises, Ltd. (until Jun 8, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.